Ka Hoʻololi ʻana o ke Kino Hoʻohuihui EML4-ALK Kanaka

Hoʻohana ʻia kēia pahu hana no ka ʻike pono ʻana i 12 mau ʻano mutation o ka gene fusion EML4-ALK i nā laʻana o nā maʻi kanesa māmā ʻaʻole liʻiliʻi ma vitro. No ka ʻike lapaʻau wale nō nā hopena hoʻāʻo a ʻaʻole pono e hoʻohana ʻia ma ke ʻano he kumu hoʻokahi no ka mālama pilikino ʻana i nā maʻi. Pono nā kauka lapaʻau e hana i nā hoʻoholo piha ma nā hopena hoʻāʻo ma muli o nā mea e like me ke kūlana o ka mea maʻi, nā hōʻailona lāʻau, ka pane lapaʻau, a me nā hōʻailona hoʻāʻo hale hana ʻē aʻe. ʻO ka maʻi kanesa māmā ka puʻupuʻu malignant maʻamau ma ka honua holoʻokoʻa, a he 80% ~ 85% o nā hihia he maʻi kanesa māmā ʻaʻole liʻiliʻi (NSCLC). ʻO ka hui ʻana o ka gene o ka echinoderm microtubule-associated protein-like 4 (EML4) a me ka anaplastic lymphoma kinase (ALK) he pahuhopu hou ia ma NSCLC, aia ʻo EML4 a me ALK i loko o nā kāʻei P21 a me P23 kanaka ma ka chromosome 2 a ua hoʻokaʻawale ʻia e kahi 12.7 miliona mau hui kumu. Ua loaʻa ma ka liʻiliʻi he 20 mau ʻano fusion, a ma waena o ia mau mea he 12 mau mutants fusion ma ka Papa 1 he mea maʻamau, kahi i ʻike ʻia ai ka mutant 1 (E13; A20), a ukali ʻia e nā mutants 3a a me 3b (E6; A20), e helu ana ma kahi o 33% a me 29% o nā maʻi me ka EML4-ALK fusion gene NSCLC, kēlā me kēia. ʻO nā mea hoʻopaʻa ALK i hōʻike ʻia e Crizotinib he mau lāʻau lapaʻau i kuhikuhi ʻia i nā molekole liʻiliʻi i hoʻomohala ʻia no nā mutations fusion gene ALK. Ma ka pale ʻana i ka hana o ka ʻāpana ALK tyrosine kinase, e ālai ana i kona mau ala hōʻailona maʻamau ʻole, a laila e pale ana i ka ulu ʻana o nā cell tumor, e hoʻokō i ka lāʻau lapaʻau i kuhikuhi ʻia no nā tumors. Ua hōʻike ʻia nā haʻawina lapaʻau he ʻoi aku ka maikaʻi o Crizotinib ma mua o 61% i nā maʻi me nā mutations fusion EML4-ALK, ʻoiai ʻaʻohe ona hopena i nā maʻi hihiu. No laila, ʻo ka ʻike ʻana i ka fusion mutation EML4-ALK ke kumu a me ke kumu no ke alakaʻi ʻana i ka hoʻohana ʻana i nā lāʻau Crizotinib.